NeoGenomics

Update in progress

NEO (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

NeoGenomics, Inc. operates cancer-focused testing laboratories in the United States and the United Kingdom. It serves hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical labs. Services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular testing, and morphologic analysis, plus oncology program support for pharma. Founded in 2001, headquartered in Fort Myers, Florida.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive